Gene-engineered T cells for cancer therapy

T cells have the capacity to eradicate diseased cells, but tumours present considerable challenges that render T cells ineffectual. Cancer cells often make themselves almost 'invisible' to the immune system, and they sculpt a microenvironment that suppresses T cell activity, survival and migration. Genetic engineering of T cells can be used therapeutically to overcome these challenges. T cells can be taken from the blood of cancer patients and then modified with genes encoding receptors that recognize cancer-specific antigens. Additional genes can be used to enable resistance to immunosuppression, to extend survival and to facilitate the penetration of engineered T cells into tumours. Using genetic modification, highly active, self-propagating 'slayers' of cancer cells can be generated.

[1]  R. Stahel,et al.  Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1) , 2012, BMC Cancer.

[2]  Martin Pule,et al.  Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. , 2011, Blood.

[3]  A. Rynda-Apple,et al.  Chimeric Antigen Receptor T Cells Shape Myeloid Cell Function within the Tumor Microenvironment through IFN-γ and GM-CSF , 2012, The Journal of Immunology.

[4]  G. Coukos,et al.  In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). , 2011, Cancer research.

[5]  Jinjuan Wang,et al.  Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. , 2008, Blood.

[6]  D. Gilham,et al.  Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T cells , 2011, Gene Therapy.

[7]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Rosenberg,et al.  In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. , 1995, Cancer research.

[9]  Yangbing Zhao,et al.  Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. , 2006, Cancer research.

[10]  H. Fine,et al.  Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. , 2012, Human gene therapy.

[11]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[12]  M. Slovak,et al.  Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  S. Eccles,et al.  Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling , 2012, Journal of Clinical Immunology.

[14]  T. Clackson,et al.  A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. , 2001, Blood.

[15]  M. Smyth,et al.  Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes. , 2004, Human gene therapy.

[16]  P. Altevogt,et al.  Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. , 2012, Gastroenterology.

[17]  Tom Royce,et al.  A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.

[18]  B. Imhof,et al.  The α vβ 3 integrin as a tumor homing ligand for lymphocytes , 2004, European journal of immunology.

[19]  Navneeta Bansal,et al.  Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies , 2012, Clinical Cancer Research.

[20]  G. Trinchieri,et al.  Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. , 2010, Cancer research.

[21]  P. Hwu,et al.  Antitumor activity of dual-specific T cells and influenza virus , 2007, Cancer Gene Therapy.

[22]  J. Massagué,et al.  Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. , 2002, Blood.

[23]  Egbert Oosterwijk,et al.  Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. , 2011, Blood.

[24]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[25]  Luigi Naldini,et al.  A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. , 2012, Blood.

[26]  H. Ikeda,et al.  Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. , 2009, Cancer research.

[27]  S. Dovedi,et al.  Natural Expression of the CD19 Antigen Impacts the Long-Term Engraftment but Not Antitumor Activity of CD19-Specific Engineered T Cells , 2010, The Journal of Immunology.

[28]  D. Schadendorf,et al.  Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  D. Campana,et al.  Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  R. Debets,et al.  T Cell Retargeting with MHC Class I-Restricted Antibodies: The CD28 Costimulatory Domain Enhances Antigen-Specific Cytotoxicity and Cytokine Production1 , 2005, The Journal of Immunology.

[31]  J. Trapani,et al.  Tumor ablation by gene-modified T cells in the absence of autoimmunity. , 2010, Cancer research.

[32]  B. Groner,et al.  Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  S. Riddell,et al.  A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. , 2011, Blood.

[34]  D. Baltimore,et al.  Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells , 2011, Proceedings of the National Academy of Sciences.

[35]  D. Powell,et al.  CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. , 2012, Blood.

[36]  M. Sadelain,et al.  Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  D. Gilham,et al.  Retroviral transduction of human peripheral blood lymphocytes with bcl-xL promotes in vitro lymphocyte survival in pro-apoptotic conditions , 2002, Gene Therapy.

[38]  S. Rosenberg,et al.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[39]  P. Coulie,et al.  About human tumor antigens to be used in immunotherapy. , 2008, Seminars in immunology.

[40]  J. Blattman,et al.  Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice. , 2010, The Journal of clinical investigation.

[41]  M. Nishimura,et al.  Retroviral transduction of peptide stimulated t cells can generate dual t cell receptor-expressing (bifunctional) t cells reactive with two defined antigens , 2004, Journal of Translational Medicine.

[42]  Z. Eshhar,et al.  Redirected tumor-specific allogeneic T cells for universal treatment of cancer. , 2011, Blood.

[43]  C. June,et al.  Enhanced function of redirected human T cells expressing linker for activation of T cells that is resistant to ubiquitylation. , 2013, Human gene therapy.

[44]  Thomas M. Schmitt,et al.  Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains , 2011, Gene Therapy.

[45]  J. Fletcher,et al.  Anti-KIT designer T cells for the treatment of gastrointestinal stromal tumor , 2013, Journal of Translational Medicine.

[46]  T. Blankenstein,et al.  A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer , 2008, Proceedings of the National Academy of Sciences.

[47]  Hao Liu,et al.  Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma , 2008, Nature Medicine.

[48]  S. Sleijfer,et al.  Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Thomas M. Schmitt,et al.  Abrogation of Src Homology Region 2 Domain-Containing Phosphatase 1 in Tumor-Specific T Cells Improves Efficacy of Adoptive Immunotherapy by Enhancing the Effector Function and Accumulation of Short-Lived Effector T Cells In Vivo , 2012, The Journal of Immunology.

[50]  K. Yanagihara,et al.  Synergistic and persistent effect of T‐cell immunotherapy with anti‐CD19 or anti‐CD38 chimeric receptor in conjunction with rituximab on B‐cell non‐Hodgkin lymphoma , 2010, British journal of haematology.

[51]  M. Essand,et al.  T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cells , 2012, Proceedings of the National Academy of Sciences.

[52]  S. Rosenberg,et al.  High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens , 2003, The Journal of Immunology.

[53]  W. Uckert,et al.  MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. , 2010, The Journal of clinical investigation.

[54]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[55]  A. Scott,et al.  Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[56]  P. Gimotty,et al.  Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy , 2008, Nature Medicine.

[57]  Tao Wang,et al.  Knockdown of human bid gene expression enhances survival of CD8+ T cells. , 2009, Immunology letters.

[58]  M. Merino,et al.  T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[59]  Hao Liu,et al.  CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. , 2011, The Journal of clinical investigation.

[60]  D. Maloney,et al.  CD 20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD 28 and 4-1 BB domains : pilot clinical trial results , 2012 .

[61]  P. Darcy,et al.  Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer. , 2011, Immunotherapy.

[62]  C. Ramos,et al.  Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy , 2011, Expert opinion on biological therapy.

[63]  S. Rosenberg,et al.  Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. , 2009, Blood.

[64]  Thomas M. Schmitt,et al.  The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. , 2010, Blood.

[65]  R. Khanna,et al.  Transduction of Primary Lymphocytes with Epstein-Barr Virus (EBV) Latent Membrane Protein-Specific T-Cell Receptor Induces Lysis of Virus-Infected Cells: A Novel Strategy for the Treatment of Hodgkin's Disease and Nasopharyngeal Carcinoma , 2006, Journal of Clinical Immunology.

[66]  Mamoru Ito,et al.  T‐cell receptor gene therapy targeting melanoma‐associated antigen‐A4 inhibits human tumor growth in non‐obese diabetic/SCID/γcnull mice , 2012, Cancer science.

[67]  T. Blankenstein,et al.  T-Cell Receptor Gene–Modified T Cells with Shared Renal Cell Carcinoma Specificity for Adoptive T-Cell Therapy , 2010, Clinical Cancer Research.

[68]  J. Trapani,et al.  A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells , 2004, Cancer Gene Therapy.

[69]  M. Sadelain,et al.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. , 2012, Blood.

[70]  M. Sadelain,et al.  T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection , 2007, Nature Medicine.

[71]  Thomas M. Schmitt,et al.  Adoptive immunotherapy of disseminated leukemia with TCR-transduced, CD8+ T cells expressing a known endogenous TCR. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[72]  S. Gottschalk,et al.  Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma , 2011, Cancer Gene Therapy.

[73]  Hiroshi Kawamoto,et al.  Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells. , 2013, Cell stem cell.

[74]  E. Kleinerman,et al.  Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. , 2012, Cancer research.

[75]  F. Marincola,et al.  IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. , 2011, The Journal of clinical investigation.

[76]  S. Rosenberg.  Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[77]  S. Forman,et al.  Efficient Selection of Genetically Modified Human T Cells Using Methotrexate-Resistant Human Dihydrofolate Reductase , 2013, Gene Therapy.

[78]  R. B. Bernstein,et al.  Achievements and Challenges , 2011 .

[79]  V. Cerundolo,et al.  Rational development of high-affinity T-cell receptor-like antibodies , 2009, Proceedings of the National Academy of Sciences.

[80]  G. Bauerschmitz,et al.  In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cells , 2004, Cancer Immunology, Immunotherapy.

[81]  C. Rooney,et al.  Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b , 2010, Journal of immunotherapy.

[82]  M. Sadelain,et al.  In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. , 2011, Cancer research.

[83]  H. Heslop,et al.  Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[84]  G. Coukos,et al.  The parallel lives of angiogenesis and immunosuppression: cancer and other tales , 2011, Nature Reviews Immunology.

[85]  G. Schuler,et al.  Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapy. , 2013, Methods in molecular biology.

[86]  H. Heslop,et al.  A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[87]  G. Hämmerling,et al.  Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. , 2002, Cancer research.

[88]  Qing He,et al.  CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.

[89]  R. Flavell,et al.  Transforming growth factor-β in T-cell biology , 2002, Nature Reviews Immunology.

[90]  P. Stern,et al.  The Role of Extracellular Spacer Regions in the Optimal Design of Chimeric Immune Receptors: Evaluation of Four Different scFvs and Antigens , 2005, Journal of immunotherapy.

[91]  F. Marincola,et al.  Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. , 2002, Human gene therapy.

[92]  D. Gilham,et al.  Targeted immunotherapy of cancer with CAR T cells: achievements and challenges , 2012, Cancer Immunology, Immunotherapy.

[93]  P. Darcy,et al.  Engineering T Cell Function Using Chimeric Antigen Receptors Identified Using a DNA Library Approach , 2013, PloS one.

[94]  Hao Liu,et al.  T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. , 2011, Blood.

[95]  H. Schmidt,et al.  Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[96]  S. Riddell,et al.  Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. , 2007, Human gene therapy.

[97]  Lei Zhang,et al.  Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer , 2012, Nature Medicine.

[98]  Michel Sadelain,et al.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.

[99]  J. Melenhorst,et al.  Aurora kinase A-specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity. , 2012, Blood.

[100]  E. Morris,et al.  Challenges in T cell receptor gene therapy , 2012, The journal of gene medicine.

[101]  Yi Li,et al.  High-Affinity TCRs Generated by Phage Display Provide CD4+ T Cells with the Ability to Recognize and Kill Tumor Cell Lines1 , 2007, The Journal of Immunology.

[102]  S. Forman,et al.  Stem-like Tumor-Initiating Cells Isolated from IL13Rα2 Expressing Gliomas Are Targeted and Killed by IL13-Zetakine–Redirected T Cells , 2012, Clinical Cancer Research.

[103]  C. Rooney,et al.  Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. , 2005, Blood.

[104]  S. Rosenberg,et al.  Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice , 2012, Clinical Cancer Research.

[105]  R. Hagedoorn,et al.  Reprogramming of Virus-specific T Cells into Leukemia-reactive T Cells Using T Cell Receptor Gene Transfer , 2004, The Journal of experimental medicine.

[106]  J W Gratama,et al.  Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR , 2000, Gene Therapy.

[107]  S. Sleijfer,et al.  Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[108]  S. Davis,et al.  Exome sequencing identifies GRIN2A as frequently mutated in melanoma , 2011, Nature Genetics.

[109]  S. Larson,et al.  Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts , 2007, Clinical Cancer Research.

[110]  B. Comin-Anduix,et al.  Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses , 2010, Proceedings of the National Academy of Sciences.

[111]  H. Heslop,et al.  An inducible caspase 9 safety switch for T-cell therapy. , 2005, Blood.

[112]  S. Rosenberg,et al.  A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity1 , 2009, The Journal of Immunology.

[113]  M. Kalos,et al.  Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[114]  S. Larson,et al.  Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 , 2003, Nature Medicine.

[115]  S. Canevari,et al.  Redirected Activity of Human Antitumor Chimeric Immune Receptors is Governed by Antigen and Receptor Expression Levels and Affinity of Interaction , 2007, Journal of immunotherapy.

[116]  B. Engels,et al.  Articles on similar topics can be found in the following Blood collections Gene Therapy (517 articles) , 2005 .

[117]  C. Megli,et al.  Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma. , 2008, Experimental hematology.

[118]  I. Pastan,et al.  Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. , 2013, Blood.

[119]  W. Burns,et al.  A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. , 2010, Cancer research.

[120]  S. Rosenberg,et al.  Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice , 2011, Clinical Cancer Research.

[121]  D. Kofler,et al.  CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack. , 2007, Cancer research.

[122]  T. Schumacher,et al.  RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells , 2010, Cancer Immunology, Immunotherapy.

[123]  David D. Smith,et al.  Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. , 2005, Blood.

[124]  W. Wilson,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[125]  A. Sette,et al.  Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. , 1995, Journal of immunology.

[126]  R. Jandial,et al.  Cytotoxic T Lymphocyte Trafficking and Survival in an Augmented Fibrin Matrix Carrier , 2012, PloS one.

[127]  M. Brenner,et al.  Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells , 2006, Leukemia.

[128]  D. Powell,et al.  A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. , 2012, Cancer research.

[129]  H. Jäck,et al.  Adjusting transgene expression levels in lymphocytes with a set of inducible promoters , 2010, The journal of gene medicine.

[130]  H. Abken,et al.  T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. , 2012, Gastroenterology.

[131]  H. Abken,et al.  IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. , 2011, Cancer research.

[132]  S. Rosenberg,et al.  Development of Human Anti-Murine T-Cell Receptor Antibodies in Both Responding and Nonresponding Patients Enrolled in TCR Gene Therapy Trials , 2010, Clinical Cancer Research.

[133]  S. Rosenberg,et al.  Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. , 2011, Cancer research.

[134]  R. Junghans,et al.  Genetically engineered T cells as adoptive immunotherapy of cancer. , 2002, Cancer chemotherapy and biological response modifiers.

[135]  S. Rosenberg,et al.  Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. , 1999, Journal of immunology.

[136]  A. Scott,et al.  Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[137]  M. Del Vecchio,et al.  Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T cells , 2009, Clinical Cancer Research.

[138]  S. Forman,et al.  Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. , 2012, Molecular immunology.

[139]  N. Cheung,et al.  Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy. , 2003, Hybridoma and hybridomics.

[140]  Z. Izsvák,et al.  The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor , 2011, Gene Therapy.

[141]  S. Rosenberg,et al.  Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[142]  Richard P. Junghans,et al.  Second-Generation Anti–Carcinoembryonic Antigen Designer T Cells Resist Activation-Induced Cell Death, Proliferate on Tumor Contact, Secrete Cytokines, and Exhibit Superior Antitumor Activity In vivo: A Preclinical Evaluation , 2008, Clinical Cancer Research.

[143]  F. Marincola,et al.  Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. , 1996, Journal of the National Cancer Institute.

[144]  H. Eom,et al.  Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models. , 2012, Blood.

[145]  K. Hynynen,et al.  Focused ultrasound delivers targeted immune cells to metastatic brain tumors. , 2013, Cancer research.

[146]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[147]  Steven A. Rosenberg,et al.  Adoptive-cell-transfer therapy for the treatment of patients with cancer , 2003, Nature Reviews Cancer.

[148]  C. Bordignon,et al.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. , 1997, Science.

[149]  Jinjuan Wang,et al.  CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. , 2012, Blood.

[150]  S. Rosenberg,et al.  Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. , 2010, Blood.

[151]  Ralf-Holger Voss,et al.  Facilitating matched pairing and expression of TCR chains introduced into human T cells. , 2007, Blood.

[152]  M. Nishimura,et al.  A Coreceptor-Independent Transgenic Human TCR Mediates Anti-Tumor and Anti-Self Immunity in Mice , 2012, The Journal of Immunology.

[153]  F. Farzaneh,et al.  Harnessing the tumour-derived cytokine, CSF-1, to co-stimulate T-cell growth and activation. , 2008, Molecular immunology.

[154]  S. Rosenberg,et al.  Bcl-2 overexpression enhances tumor-specific T-cell survival. , 2005, Cancer research.

[155]  S. Rosenberg,et al.  Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. , 2007, Cancer research.

[156]  Bent K. Jakobsen,et al.  Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions , 2008, The Journal of Immunology.

[157]  I. Pastan,et al.  Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains , 2009, Proceedings of the National Academy of Sciences.

[158]  Michel Sadelain,et al.  Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells , 2012, Nature Biotechnology.

[159]  P. Hwu,et al.  Generation of gene-modified T cells reactive against the angiogenic kinase insert domain-containing receptor (KDR) found on tumor vasculature. , 2000, Human gene therapy.

[160]  M. Trivett,et al.  The Lewis-Y Carbohydrate Antigen is Expressed by Many Human Tumors and Can Serve as a Target for Genetically Redirected T cells Despite the Presence of Soluble Antigen in Serum , 2009, Journal of immunotherapy.

[161]  G. Ashton,et al.  Eradication of Established B-cell Lymphoma by CD19-specific Murine T Cells is Dependent on Host Lymphopenic Environment and Can be Mediated by CD4+ and CD8+ T Cells , 2009, Journal of immunotherapy.

[162]  J. Waxman,et al.  CD3 limits the efficacy of TCR gene therapy in vivo. , 2011, Blood.

[163]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[164]  Gang Wang,et al.  A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer , 2006, Clinical Cancer Research.

[165]  T. Schumacher,et al.  TCR Gene Therapy of Spontaneous Prostate Carcinoma Requires In Vivo T Cell Activation1 , 2008, The Journal of Immunology.

[166]  Adam Bagg,et al.  Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. , 2013, Blood.

[167]  C. Klebanoff,et al.  Paths to stemness: building the ultimate antitumour T cell , 2012, Nature Reviews Cancer.

[168]  Tongguang Wang,et al.  Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy , 2013, Journal of immunotherapy.

[169]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[170]  M. Grez,et al.  An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[171]  M. V. van Loenen,et al.  Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies , 2009, Haematologica.

[172]  M. Sadelain,et al.  How do CARs work? , 2012, Oncoimmunology.

[173]  S. H. van der Burg,et al.  Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer , 2011, Journal of Translational Medicine.

[174]  Hans J. Stauss,et al.  Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer , 2001, Nature Immunology.

[175]  C. Rooney,et al.  T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[176]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[177]  J. Wargo,et al.  A TCR Targeting the HLA-A*0201–Restricted Epitope of MAGE-A3 Recognizes Multiple Epitopes of the MAGE-A Antigen Superfamily in Several Types of Cancer , 2011, The Journal of Immunology.

[178]  G. Adams,et al.  T Cell Activation by Antibody-Like Immunoreceptors: Increase in Affinity of the Single-Chain Fragment Domain above Threshold Does Not Increase T Cell Activation against Antigen-Positive Target Cells but Decreases Selectivity1 , 2004, The Journal of Immunology.

[179]  P. Hwu,et al.  Dual-specific T cells combine proliferation and antitumor activity , 2002, Nature Biotechnology.

[180]  S. Rosenberg,et al.  Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity , 2008, Proceedings of the National Academy of Sciences.

[181]  H. Abken,et al.  Eradication of melanomas by targeted elimination of a minor subset of tumor cells , 2011, Proceedings of the National Academy of Sciences.

[182]  A. Scott,et al.  Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. , 2000, Cancer research.

[183]  R. Debets,et al.  Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR αβ gene transfer requires CD8α , 2005, Gene Therapy.

[184]  W. Wilson,et al.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.

[185]  H. Abken,et al.  Building better chimeric antigen receptors for adoptive T cell therapy. , 2010, Current gene therapy.

[186]  E. Warren,et al.  Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. , 2006, Blood.

[187]  A. Bertoletti,et al.  Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. , 2011, Journal of hepatology.

[188]  I. Jeremias,et al.  TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo. , 2012, Blood.

[189]  H. Heslop,et al.  T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. , 2009, Blood.